

(19) World Intellectual Property
Organization
International Bureau



Rec'd PCT/PTO 10 JUN 2005
10/538880

(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052405 A1

(51) International Patent Classification⁷: A61K 47/48

(21) International Application Number:
PCT/KR2003/002700

(22) International Filing Date:
10 December 2003 (10.12.2003)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
10-2002-0078778
11 December 2002 (11.12.2002) KR

(71) Applicants (for all designated States except US): CHONG KUN DANG PHARMACEUTICAL CORP. [KR/KR]; 368, Chungjungro 3-ga, Seodaemun-gu, Seoul 120-756 (KR). MC TECHNOLOGIES, INC. [US/US]; 410 Chipeta Way, Suite 209, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HONG, CHUNG-IL [US/US]; 4446, West Berteau Avenue, Chicago, IL 60641-1097 (US). SHIN, Hee-Jong [KR/KR]; 1404-101, Yeonhwamaeul, Jung 2-dong, Wonmi-gu, Bucheon-si 420-022 (KR). KI, Min-Hyo [KR/KR]; 102-105, Shindonga APT, Shinbang-dong,

Cheonan-si, Chungcheongnam-do 330-766 (KR). CHOI, Mee-Hwa [KR/KR]; 102-323, Joyang APT, 252, Jeo-ri, Seonggeo-eub, Cheonan-si, Chungcheongnam-do 330-836 (KR).

(74) Agent: LEE, Byung-Hyun; #705, New Seoul Bldg., 828-8,, Yeoksam-dong, Kangnam-gu, Seoul 135-080 (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: ORAL FORMULATIONS FOR POORLY ABSORPTIVE HYDROPHILIC DRUGS



(57) Abstract: Disclosed herein is a pharmaceutical composition for oral absorption of polar drugs. The composition consists essentially of (a) at least one polar active substance having a bioavailability of less than 30% which is poorly absorptive through lipid membranes because of its high hydrophilicity and charged ion; (b) at least one organic alkalizing agent having an amino acid or polyol structure which shows alkalinity in aqueous solution and is ionically bonded to the polar active substance; and (c) at least one surfactant having a C₆₋₁₈ fatty acid structure which has an HLB of 4 to 18. Alternatively, the composition consists essentially of (d) at least one organic alkalizing agent having the characteristics of both the organic alkalizing agent and the surfactant instead of the organic alkalizing agent and the surfactant. The composition enables polar active drugs to penetrate the gastro-intestinal membrane and oral dosage forms to be substituted for injections.

WO 2004/052405 A1